BRIEF-Karyopharm says top-line data from SADAL study expected in second half of 2018
* Karyopharm reports updated Phase 2b SADAL data for Selinexor in diffuse large B-cell lymphoma at the 2017 European Hematology Association Annual Meeting
March 17 NCR Corp
* CEO William Nuti's FY 2016 total compensation $19.2 million versus $11.95 million in FY 2015 - SEC filing
* CFO Robert Fishman's FY 2016 total compensation $6.1 million versus $2.5 million in FY 2015 Source text: (bit.ly/2mB5eBH) Further company coverage:
* Analysts say internet companies can adjust to new rules (Recasts, adds context, analyst comment, user comments)
LONDON, June 23 Investors pulled $7.7 billion from U.S. equities, the biggest outflows in five weeks, data from Bank of America Merrill Lynch (BAML) showed on Friday, reversing the previous week's bumper inflows as bears battled with the bulls.